Figs Inc vs Relay Therapeutics Inc. Common Stock — how do they compare? Figs Inc trades at $15 (market cap $2.34B), while Relay Therapeutics Inc. Common Stock trades at $17.39 (market cap $3.94B). The key difference: Relay Therapeutics Inc. Common Stock is the larger of the two by market cap, and Figs Inc is more actively traded (6,865,366 versus 3,432,928). Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 33 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| FIGS | RLAY | |
|---|---|---|
Market Cap | $2.34B | $3.94B |
Volume | 6,865,366 | 3,432,928 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $20.75 |
52-Week Low | $6.90 | $6.03 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $2.10B | $3.06B |
Signals from Pluang's Aura AI — not financial advice
FIGS stock trades at $14.98, up 6.24% today, with strong technical momentum and bullish moving averages. The company shows accelerating revenue growth, with 2025 revenue reaching $631.10M and net income of $34.25M. Recent earnings beats and raised 2026 guidance signal operational strength, though valuation multiples remain elevated with a P/E of 42.61. International expansion continues to drive growth, with Q2 international sales surging 67%.
The outlook remains positive with analyst consensus pointing to 26.4% upside potential to $18.00 target. Strong fundamentals and momentum are balanced by rich valuation requiring continued execution. Key risks include premium pricing pressure and competitive threats in healthcare apparel. Wall Street sentiment leans bullish with 60% buy ratings among 15 analysts covering the stock.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →